Alice P Chen
National Cancer Institute LAO · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
21
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
16 more share only the name and are not shown
Trial papers
80
PubMed author-name match
Trials
Studies that name Alice P Chen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:22 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05691517 · Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid CancersNational Cancer Institute (NCI) · recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph3NCT04924608 · Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform NeurofibromasAstraZeneca · active not recruiting · Neurofibromatosis 1, Plexiform Neurofibroma (PN) · principal investigator
- Ph2NCT04449549 · Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelNational Cancer Institute (NCI) · recruiting · Neoplasms · principal investigator
- N/ANCT03269578 · Sample Collection and Tracking for the Developmental Therapeutics ClinicNational Cancer Institute (NCI) · recruiting · Neoplasms, Lymphoma · principal investigator
- Ph2NCT03141684 · Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaNational Cancer Institute (NCI) · active not recruiting · Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma · principal investigator
- Ph1NCT03030417 · Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and LymphomasNational Cancer Institute (NCI) · completed · Solid Tumors, Lymphoma · principal investigator
- Ph1NCT02723864 · Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid TumorsNational Cancer Institute (NCI) · completed · Neoplasms · principal investigator
- Ph1NCT02379416 · Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsNational Cancer Institute (NCI) · completed · Solid Tumors · principal investigator
- Ph1NCT02211755 · Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsNational Cancer Institute (NCI) · completed · Neoplasms, Myelodysplastic Syndromes, Lymphomas · principal investigator
- Ph1NCT02192541 · Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and SarcomasNational Cancer Institute (NCI) · terminated · Neoplasms · principal investigator
- Ph1/Ph2NCT01989546 · Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA MutationsNational Cancer Institute (NCI) · completed · Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer · principal investigator
- Ph1/Ph2NCT01851369 · TRC102 and Temozolomide for Relapsed Solid Tumors and LymphomasNational Cancer Institute (NCI) · completed · Lymphomas, Solid Tumors, NSCLC · principal investigator
- Ph1NCT01794104 · Indenoisoquinoline LMP400 for Advanced Solid Tumors and LymphomasNational Cancer Institute (NCI) · completed · Neoplasm, Lymphoma · principal investigator
- Ph2NCT01755195 · Cabozantinib for Adults With Advanced Soft Tissue SarcomaNational Cancer Institute (NCI) · completed · Refractory Soft Tissue Sarcomas · principal investigator
- Ph1NCT01581541 · PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard TreatmentNational Cancer Institute (NCI) · terminated · Solid Tumors, Lymphoma · principal investigator
- Ph1NCT01468922 · Pazopanib and ARQ 197 for Advanced Solid TumorsNational Cancer Institute (NCI) · completed · Solid Tumor · principal investigator
- Ph2NCT01391962 · Sunitinib or Cediranib for Alveolar Soft Part SarcomaNational Cancer Institute (NCI) · completed · Sarcoma, Alveolar Soft Part · principal investigator
- Ph1NCT01273168 · Endoxifen in Adults With Hormone Receptor Positive Solid TumorsNational Cancer Institute (NCI) · completed · Hormone Receptor-Positive Breast, Gynecologic, Desmoid · principal investigator
- Ph1NCT01246102 · AT13387 in Adults With Refractory Solid TumorsNational Cancer Institute (NCI) · completed · Solid Tumors, Breast Cancer · principal investigator
- Ph1NCT01051635 · A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and LymphomasNational Cancer Institute (NCI) · completed · Neoplasms, Lymphoma · principal investigator
- Ph2NCT00942877 · Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part SarcomaNational Cancer Institute (NCI) · completed · Sarcoma, Alveolar Soft Part · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 16 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:22 UTC. The ranking covers the 200 most relevant of 80 PubMed records, and a shared surname and initials can bring in a namesake. All 80 on PubMed
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.J Clin Oncol · 2020341 citationsRCR 14.0
- 305 citationsRCR 12.3
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.J Clin Oncol · 2015287 citationsRCR 7.6
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).J Clin Oncol · 2020242 citationsRCR 8.4
- 183 citationsRCR 3.5
- Atezolizumab for Advanced Alveolar Soft Part Sarcoma.N Engl J Med · 2023148 citationsRCR 11.6
- Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).J Clin Oncol · 2017142 citationsRCR 4.4
- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.Eur J Cancer · 2018135 citationsRCR 4.2
- Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.J Clin Oncol · 2020129 citationsRCR 5.0
- Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.J Clin Oncol · 2020115 citationsRCR 4.1